荷兰性别中立人乳头瘤病毒疫苗接种项目的成本效果分析
该研究采用静态马尔可夫模型模拟10万名12岁荷兰男孩,评估在现有女孩接种覆盖率基础上增加男孩HPV疫苗接种的健康与经济效果。结果显示接种30%男孩可预防18例肛门癌、13例阴茎癌和25例口咽癌,节省205个质量调整生命年(QALY);考虑女性群体额外获益后,总体增量成本效果比(ICER)为每QALY 7310欧元。结论认为在荷兰当前情况下男孩HPV疫苗接种可能具有成本效果。
要点
- 接种30%的12岁男孩可预防18例肛门癌、13例阴茎癌和25例口咽癌。
- 男孩接种直接节省205个QALY,ICER为每QALY 17907欧元(疫苗价格50欧元/剂)。
- 考虑女性群体额外获益后,总体ICER降至每QALY 7310欧元。
核心结论
- 在女孩接种基础上增加男孩HPV疫苗接种,可在男孩和女孩中预防相当数量的癌症。
- 基于荷兰当前情况,男孩HPV疫苗接种可能具有成本效果。
研究设计与样本
- 采用静态马尔可夫模型,终身时间跨度,模拟10万名12岁荷兰男孩的队列。
- 模型比较HPV疫苗接种的健康和经济效果,并考虑当前女孩疫苗接种覆盖率。
- 男孩HPV患病率已根据2017年女孩项目的预测群体效应进行校正。
- 转移概率取自同行评议文献和既往构建的模型,并通过多重敏感性分析检验稳健性。
主要发现
- 接种30%的10万名12岁男孩可预防18例肛门癌、13例阴茎癌和25例口咽癌。
- 男孩接种直接节省205个QALY。
- 假设疫苗价格为每剂50欧元,增量成本效果比(ICER)为每QALY 17907欧元。
- 由于疫苗诱导的群体效应,预计女性队列额外预防110例癌症并获得246个QALY。
- 综合男孩和女孩的额外获益,总预防166例癌症,获得451个QALY,总体ICER为每QALY 7310欧元。
关键数值与推荐
- 男孩接种覆盖率30%时,预防18例肛门癌、13例阴茎癌和25例口咽癌。
- 男孩接种直接节省205个QALY,ICER为每QALY 17907欧元(疫苗价格50欧元/剂)。
- 考虑女性群体额外获益后,总体ICER为每QALY 7310欧元。
- 模型结果对疫苗价格、女性群体免疫和疫苗效力的变化最为敏感。
临床怎么用
- 在女孩HPV疫苗接种覆盖率不高的地区,可考虑将男孩纳入接种策略以提升群体保护。
- 决策时应综合考虑男孩直接获益及对女性的间接群体效应。
- 成本效果受疫苗价格影响显著,定价策略是推广男孩接种的关键考量。
局限性
- 模型为静态马尔可夫模型,可能无法完全捕捉动态传播效应。
- 结果对疫苗价格、女性群体免疫和疫苗效力等参数敏感,存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccinating girls against human papillomavirus (HPV) infection is a highly effective and cost-effective intervention to provide protection against HPV-induced cancers. Since vaccination coverage rates among girls is modest in the Netherlands, additional strategies should be implemented to improve the protection against HPV-related cancer. Here we assessed the benefits and cost-effectiveness of gender-neutral vaccination. METHODS: We designed a static Markov model with a lifelong time horizon to simulate a cohort of 100,000 12-year-old Dutch boys. The model compares health and economic effects of HPV vaccination taking the current female vaccination coverage into consideration. HPV prevalence in boys was corrected for the predicted herd effects of the female programme in 2017. We extracted transition probabilities from peer-reviewed literature and previously constructed models. The robustness of the model was tested with multiple sensitivity analyses. RESULTS: Vaccinating 30% of 100,000 12-year-old boys prevents 18, 13 and 25 cases of anal, penile, and oropharyngeal cancers in men, respectively. A total of 205 quality-adjusted life-years (QALYs) are saved by preventing cancer-related morbidity and mortality. Assuming a vaccine price of €50 per dose, the incremental cost-effectiveness ratio (ICER) is €17,907 per QALY. In addition, due to vaccine-induced herd effects, we estimated that 110 cases of cancer in females would be additionally prevented and 246 QALYs would be gained in the female cohort, bringing the total to 166 cancers prevented and 451 QALYs gained. Taking these additional benefits of boys' vaccination into account, the overall ICER was estimated at €7310 per QALY gained. The model outcomes are most sensitive to variation in vaccine price, herd immunity from females and vaccine efficacy. CONCLUSIONS: Vaccination of boys, additional to girls, will prevent a relevant number of cancers in both boys and girls. Based on the current Dutch situation vaccination of HPV in boys is likely cost-effective. GSK Study identifier: HO-18-19169.
引用
- Simons JJM, Vida N, Westra TA, et al. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. Vaccine. 2020. PMID: 32451211. doi:10.1016/j.vaccine.2020.05.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。